JP4951204B2 - 組換えアデノウイルスベクターとその応用 - Google Patents
組換えアデノウイルスベクターとその応用 Download PDFInfo
- Publication number
- JP4951204B2 JP4951204B2 JP2004542569A JP2004542569A JP4951204B2 JP 4951204 B2 JP4951204 B2 JP 4951204B2 JP 2004542569 A JP2004542569 A JP 2004542569A JP 2004542569 A JP2004542569 A JP 2004542569A JP 4951204 B2 JP4951204 B2 JP 4951204B2
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- plasmid
- region
- genome
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims description 91
- 239000013598 vector Substances 0.000 title description 24
- 239000013612 plasmid Substances 0.000 claims description 110
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 37
- 230000003362 replicative effect Effects 0.000 claims description 32
- 241000701114 Canine adenovirus 2 Species 0.000 claims description 24
- 238000012217 deletion Methods 0.000 claims description 22
- 230000037430 deletion Effects 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 108091026890 Coding region Proteins 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 11
- 230000010076 replication Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000002458 infectious effect Effects 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000008488 polyadenylation Effects 0.000 claims description 4
- 101150029662 E1 gene Proteins 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 76
- 241000700605 Viruses Species 0.000 description 42
- 101150047856 Cav2 gene Proteins 0.000 description 31
- 240000000220 Panda oleosa Species 0.000 description 17
- 235000016496 Panda oleosa Nutrition 0.000 description 17
- 238000003780 insertion Methods 0.000 description 17
- 230000037431 insertion Effects 0.000 description 17
- 238000010276 construction Methods 0.000 description 14
- 241000282326 Felis catus Species 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 241000282465 Canis Species 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 229960000723 ampicillin Drugs 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 241000701157 Canine mastadenovirus A Species 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 101150075174 E1B gene Proteins 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 108020005202 Viral DNA Proteins 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000598171 Human adenovirus sp. Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282421 Canidae Species 0.000 description 2
- 241001466804 Carnivora Species 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100038909 Caveolin-2 Human genes 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710199711 Early E1A protein Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000725579 Feline coronavirus Species 0.000 description 1
- 241000701925 Feline parvovirus Species 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 101150009243 HAP1 gene Proteins 0.000 description 1
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000589924 Leptospira sp. Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000188845 Porcine adenovirus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
・かかる複製型ウイルスが拡散するおそれに関連するバイオセイフティーの問題があること、
・感染細胞によって大量のウイルス粒子が産生されることによりベクターに対する高い免疫応答の誘導が引き起こされ、追加免疫の有効性が制限されること、
・感染によって破壊された細胞から塩析したワクチン抗原が母親の抗体によって中和されることにより、若い個体におけるこれらの複製型ベクターの有効性が低下すること、である。
・イヌアデノウイルス2型のゲノムの311位と319位との間に位置する領域に対応する、元の複製型アデノウイルスのゲノム領域の全体または一部、および/または、
・イヌアデノウイルス2型のゲノムの400位と439位との間に位置する領域に対応する、元の複製型アデノウイルスのゲノム領域の全体または一部;この欠失により、(Cav2 GenBank J04368配列の409位に位置する)E1AのプロモーターのTATAボックスがとくに削除される;および/または、
・イヌアデノウイルス2型のゲノムの438位と499位との間に位置する領域に対応する、元の複製型アデノウイルスのゲノム領域の全体または一部;この欠失により(Cav2 GenBank J04368配列内の439位に位置する)E1Aの転写開始部位がとくに削除される;
を含むことができる。
・ワクチン抗原のコード遺伝子、例えば、ネコ免疫不全ウイルス(FIV)のgag遺伝子もしくはenv遺伝子、ネココロナウイルスのSタンパク質、Mタンパク質もしくはNタンパク質、イヌまたはネコのパルボウイルスのキャプシドタンパク質、狂犬病ウイルスの糖タンパク質G、またはレプトスピラsp.のHap−1タンパク質、など
・遺伝子治療に利用できる修正遺伝子、例えば、エリスロポエチン(Epo)、血管内皮細胞増殖因子(VEGF)、ニューロトロフィン3(NT−3)、または心房性ナトリウム利尿因子(ANF)の修正遺伝子、など
・癌治療に利用できる遺伝子、例えば、IL−2遺伝子、IFNγ遺伝子、
などがある。
1)アデノウイルスのゲノム(レシピエント分子)内に挿入される異種DNA断片(ドナー分子)が、アンピシリンおよびカナマイシンに対するそれらの二重の耐性に基づいて組換えプラスミドを単離することを可能にする選択マーカーを含んでいる、また
2)前記断片が、環状で、もしくは挿入部位の外側に位置する制限部位における切断によって線状化された形で、レシピエント分子と共形質転換される、
という点である。
α)(i)アデノウイルスのゲノムおよび第一の選択遺伝子を含むプラスミド;および(ii)前記プラスミドにおける挿入を実施する部位が伴う配列と相同の配列を伴った、前記ゲノム内に挿入するための異種配列を含み、さらに第一のものとは異なる第二の選択遺伝子を含んだ、あらかじめ線状化されたDNA断片;を、前記原核細胞内へ導入する過程と、
β)第一および第二の選択遺伝子を発現する組換えプラスミドを含む細胞の作成と選択を可能にするために、選択的条件で前記原核細胞を培養する過程と、
γ)選択した細胞から、前記組換えアデノウイルスのゲノムを単離する過程、
とから成ることを特徴とする。
・下記から構成されるグループにおいて選択されたいっさいの核酸分子:
a)先に定義したような本発明による組換えアデノウイルスのゲノムに相当する核酸分子、および
b)欠失部分の上流に位置する元の複製型アデノウイルスの配列を10から1000bpの間、好適には少なくとも300bp有し、また欠失部分の下流に位置する元の複製型アデノウイルスの配列を10から5000bpの間、好適には10と1000bpの間、さらに好適には少なくとも300bp有する、上述のa)の分子の断片によって構成される核酸分子(かかる分子は、さらに、欠失部分の代わりに、あるいは欠失部分の近傍に挿入された異種配列の全体または一部を含むことができる)。
・先に定義したa)またはb)の核酸分子を含む、いっさいの核酸ベクター、とくにいっさいのプラスミド。
断片A
5’−TTGGCGCGCCCATCATCAATAATATACAGGAC−3’(SEQ ID NO:1)
5’−GCTCTAGACCTGCCCAAACATTTAACC−3’ (SEQ ID NO:2)
断片B
5’−TTGGCGCGCCCATCATCAATAATATACAGGAC−3’(SEQ ID NO:1)
5’−GCTCTAGAGGGTGATTATTAACAACGTC−3’ (SEQ ID NO:3)
5’−TTGGCGCCCATCATCAATAATATACAGGAC−3’(SEQ ID NO:1)
5’−CCGACGTCGACCATAAACTTTGACATTAGCCG−3’(SEQ ID NO:4)
5’−GCTCTAGAGCGAAGATCTCCAACAGCAATACACTCTTG−3’(SEQ ID NO:5)
5’−GCTCTAGACCTGCCCAAACATTTAACC−3’ (SEQ ID NO:2)
5’−GATAAGGATCACGCGGCCTTAAATTCTCAG−3’(SEQ ID NO:6)
5’−GCTCTAGACCTGCCCAAACATTTAACC−3’ (SEQ ID NO:2)
5’−GATAAGGATCAACAGAAACACTCTGTTCTCTG−3’(SEQ ID NO:7)
5’−GCTCTAGACCTGCCCAAACATTTAACC−3’ (SEQ ID NO:2)
5’−AGCTTTGTTTAAACGGCGCGCCGGGATTTTGGTCATGAAC−3’(SEQ ID NO:8)
5’−CCGGCGCGCCGTTTAAACAAAGCTATCCGCTCATGAA−3’ (SEQ ID NO:9)
・単離したウイルスCav311−439/CMVeGFP、Cav311−401/CMVeGFPならびにCav311−319/CMVeGFPの制限酵素のプロフィールと配列は、所期のものと合致している、
・精製したウイルスCav311−439/CMVeGFP、Cav311−401/CMVeGFPならびにCav311−319/CMVeGFPの力価は、約109.2pfu/mlである。
・導入遺伝子の高い発現レベルが、ウイルスCav311−439 CMVeGFPに感染させた細胞で認められること、
・変更されていないイヌの細胞(DK細胞)またはこのウイルスCav311−439/CMVeGFPに感染させたネコの細胞では細胞変性効果がいっさい認められなかったのに対して、E1領域を発現する、このウイルスCav311−439/CMVeGFPに感染させたイヌの細胞にのみ大きな細胞変性効果が認められたこと、
・コントロールにおいて、野生型Cav(Cav2)に感染させたイヌの細胞(DKとDK/E1−28)では大きな細胞変性効果が認められたのに対して、Cav2に感染させたネコの細胞では細胞変性効果がいっさい認められないこと、である。
・ウイルスCav311−439 CMVeGFPが、試験したイヌおよびネコの株内でそのゲノムを複製すること、
・複製レベルが、ネコの細胞内よりもイヌの細胞内での方が高いこと、
・複製のピークに達するのが、DK/E1−28細胞内が24時間後、DK細胞内が48時間後であり、おそらくDK/E1−28細胞内のE1領域の細胞による発現がその理由であること、である。
1区(n=2):9.6×107pfu
2区(n=2):9.6×106pfu
3区(n=2):コントロール
5’−CGGCCGACTCTTGAGTGCGCAGCGAGA−3’(SEQ ID NO:10)
5’−GGCGCGCCGAGAGACAACGCTGGACACGG−3’(SEQ ID NO:11)
1区(n=4):Cav311−319 eGFP
2区(n=4):Cav311−319 CONTROL
3区(n=1):非接種であるコントロール
Claims (13)
- 配列番号12の311位と319位との間のセグメントが欠失した、複製および感染性ウイルス粒子の産生が可能な組換えイヌアデノウイルス2型であって、前記アデノウイルスが、E1Aのコード配列の全体、およびその下流に位置するE1遺伝子領域の全体を保持し、前記領域が、E1Aのポリアデニル化シグナルおよびE1B領域を含むことを特徴とする、組換えアデノウイルス。
- 複製型イヌアデノウイルス2型のE1、E2、およびE4コード領域、ならびに右および左ITRを包含することを特徴とする、請求項1に記載の組換えアデノウイルス。
- 複製型イヌアデノウイルス2型のE1、E2、およびE4コード領域、右および左ITR、ならびにE3コード領域を包含することを特徴とする、請求項1に記載の組換えアデノウイルス。
- 欠失部分が、さらに、
・配列番号12の400位と439位との間に位置する領域に対応する、複製型イヌアデノウイルス2型のゲノム領域の全体または一部、および/または
・配列番号12の438位と499位との間に位置する領域に対応する、複製型イヌアデノウイルス2型のゲノム領域の全体または一部、
を含むことを特徴とする、請求項1から3のいずれか一つに記載の組換えアデノウイルス。 - さらにそのゲノム内に挿入された関心のある異種ポリヌクレオチド配列を含むことを特徴とする、請求項1から4のいずれか一つに記載の組換えアデノウイルス。
- 前記異種配列が、配列番号12の311位と319位との間に位置する領域に対応するゲノム領域に挿入されることを特徴とする、請求項5に記載の組換えアデノウイルス。
- 請求項1から6のいずれか一つに記載の組換えアデノウイルスを含むことを特徴とする医薬品。
- 核酸分子であって、
a)請求項1から6のいずれか一つに記載の組換えアデノウイルスのゲノムに相当する核酸分子、および
b)欠失部分の上流に位置する複製型イヌアデノウイルス2型の配列を10と1000bpの間有し、また欠失部分の下流に位置する複製型イヌアデノウイルス2型の配列を10と5000bpの間有する、上述のa)の分子の断片によって構成される核酸分子、
から構成されるグループにおいて選択されることを特徴とする、核酸分子。 - 複製型イヌアデノウイルス2型における欠失部分の下流の配列の少なくとも10から1000bpをさらに含むことを特徴とする、請求項8に記載の核酸。
- 請求項8または9に記載の核酸分子を包むことを特徴とする、プラスミド。
- ペプチドまたはタンパク質に特異的な免疫応答を誘導するための方法であって、
特異的なペプチドまたはタンパク質をコードする異種ポリヌクレオチドがゲノムに含まれる請求項1から6のいずれか一つに記載の組換えアデノウイルスを、その投与を必要とする対象(ヒトを除く)に投与することを含むことを特徴とする方法。 - 特異的なペプチドまたはタンパク質に対する抗体の産生を刺激することを含むことを特徴とする、請求項11に記載の方法。
- 特異的なペプチドまたはタンパク質をコードする異種ポリヌクレオチドが、組換えアデノウイルスのゲノムの311位と319位との間に導入される、請求項11または12に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0212472A FR2845395B1 (fr) | 2002-10-08 | 2002-10-08 | Vecteurs adenoviraux recombinants et leurs applications |
FR02/12472 | 2002-10-08 | ||
PCT/FR2003/002964 WO2004033696A2 (fr) | 2002-10-08 | 2003-10-08 | Vecteurs adenoviraux recombinants et leurs applications |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006501835A JP2006501835A (ja) | 2006-01-19 |
JP4951204B2 true JP4951204B2 (ja) | 2012-06-13 |
Family
ID=32011498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004542569A Expired - Lifetime JP4951204B2 (ja) | 2002-10-08 | 2003-10-08 | 組換えアデノウイルスベクターとその応用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8119396B2 (ja) |
EP (1) | EP1549751A2 (ja) |
JP (1) | JP4951204B2 (ja) |
AU (1) | AU2003283504B2 (ja) |
CA (1) | CA2501633A1 (ja) |
FR (1) | FR2845395B1 (ja) |
WO (1) | WO2004033696A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015222153A1 (en) * | 2014-02-28 | 2016-09-01 | Beth Israel Deaconess Medical Center Inc. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
CA3036293A1 (en) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | New promoters |
UY37406A (es) | 2016-09-20 | 2018-03-23 | Boehringer Ingelheim Vetmedica Gmbh | Nuevo sitio de inserción orf70 de ehv |
CN109715219B (zh) | 2016-09-20 | 2024-03-01 | 勃林格殷格翰动物保健有限公司 | 犬腺病毒载体 |
EP3515480A1 (en) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New swine influenza vaccine |
KR102601875B1 (ko) * | 2020-03-25 | 2023-11-14 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
EP1248851A2 (en) * | 1999-12-07 | 2002-10-16 | Genethon III | Canine adenovirus vectors for the transfer of genes in targeted cells |
-
2002
- 2002-10-08 FR FR0212472A patent/FR2845395B1/fr not_active Expired - Fee Related
-
2003
- 2003-10-08 CA CA002501633A patent/CA2501633A1/fr not_active Abandoned
- 2003-10-08 AU AU2003283504A patent/AU2003283504B2/en not_active Ceased
- 2003-10-08 EP EP03775478A patent/EP1549751A2/fr not_active Withdrawn
- 2003-10-08 WO PCT/FR2003/002964 patent/WO2004033696A2/fr active Application Filing
- 2003-10-08 US US10/530,712 patent/US8119396B2/en not_active Expired - Lifetime
- 2003-10-08 JP JP2004542569A patent/JP4951204B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20060233756A1 (en) | 2006-10-19 |
AU2003283504B2 (en) | 2009-06-04 |
FR2845395A1 (fr) | 2004-04-09 |
JP2006501835A (ja) | 2006-01-19 |
FR2845395B1 (fr) | 2008-05-30 |
CA2501633A1 (fr) | 2004-04-22 |
US8119396B2 (en) | 2012-02-21 |
WO2004033696A2 (fr) | 2004-04-22 |
AU2003283504A1 (en) | 2004-05-04 |
WO2004033696A3 (fr) | 2004-05-27 |
EP1549751A2 (fr) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2219241C2 (ru) | Дефектный рекомбинантный аденовирусный вектор (варианты) | |
AU711366B2 (en) | Complementary adenoviral vector systems and cell lines | |
KR100510822B1 (ko) | 재조합 아데노바이러스 제조용 세포 | |
JP6277213B2 (ja) | サルアデノウイルスベクターの増殖方法 | |
JP2005503797A (ja) | アデノウイルスベクター及び関連する系、並びに製造及び使用の方法 | |
CZ302895A3 (en) | The use of recombinant adenovirus of animal origin for preparing a pharmaceutical preparation | |
US20210269827A1 (en) | Modified serotype 28 adenoviral vectors | |
KR20190019147A (ko) | 강력하고 균형 잡힌 양방향성 프로모터 | |
JP2008054680A (ja) | ウシアデノウイルスタイプ3ゲノム | |
KR100484441B1 (ko) | IVa2유전자가불활성화된결손재조합아데노바이러스 | |
JP4951204B2 (ja) | 組換えアデノウイルスベクターとその応用 | |
MXPA97001766A (en) | Defective recombinant adenovirus with a vat iva2 inactiv | |
AU752148B2 (en) | Chimeric adenoviral vectors | |
US6642052B2 (en) | Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease | |
EP1291434A2 (en) | Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease | |
JP2023520610A (ja) | 真核細胞におけるdna断片の維持、手法、および使用 | |
JP3713038B2 (ja) | 組換えアデノウイルス | |
Wilson | Adenoviruses as Vectors for Human Gene Therapy | |
AU2002327630A1 (en) | Adenoviral vector and related system and methods of making and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20060526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060526 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090826 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090925 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091023 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110127 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110216 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110223 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20111102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111102 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120312 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150316 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4951204 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |